These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

456 related articles for article (PubMed ID: 25107680)

  • 1. Assessment of herd immunity and cross-protection after a human papillomavirus vaccination programme in Australia: a repeat cross-sectional study.
    Tabrizi SN; Brotherton JM; Kaldor JM; Skinner SR; Liu B; Bateson D; McNamee K; Garefalakis M; Phillips S; Cummins E; Malloy M; Garland SM
    Lancet Infect Dis; 2014 Oct; 14(10):958-66. PubMed ID: 25107680
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human papillomavirus in young women with Chlamydia trachomatis infection 7 years after the Australian human papillomavirus vaccination programme: a cross-sectional study.
    Chow EP; Danielewski JA; Fehler G; Tabrizi SN; Law MG; Bradshaw CS; Garland SM; Chen MY; Fairley CK
    Lancet Infect Dis; 2015 Nov; 15(11):1314-23. PubMed ID: 26201300
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence of human papillomavirus in young men who have sex with men after the implementation of gender-neutral HPV vaccination: a repeated cross-sectional study.
    Chow EPF; Tabrizi SN; Fairley CK; Wigan R; Machalek DA; Garland SM; Cornall AM; Atchison S; Hocking JS; Bradshaw CS; Balgovind P; Murray GL; Chen MY
    Lancet Infect Dis; 2021 Oct; 21(10):1448-1457. PubMed ID: 34043963
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quadrivalent vaccine-targeted human papillomavirus genotypes in heterosexual men after the Australian female human papillomavirus vaccination programme: a retrospective observational study.
    Chow EPF; Machalek DA; Tabrizi SN; Danielewski JA; Fehler G; Bradshaw CS; Garland SM; Chen MY; Fairley CK
    Lancet Infect Dis; 2017 Jan; 17(1):68-77. PubMed ID: 27282422
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fall in human papillomavirus prevalence following a national vaccination program.
    Tabrizi SN; Brotherton JM; Kaldor JM; Skinner SR; Cummins E; Liu B; Bateson D; McNamee K; Garefalakis M; Garland SM
    J Infect Dis; 2012 Dec; 206(11):1645-51. PubMed ID: 23087430
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Final analysis of a study assessing genital human papillomavirus genoprevalence in young Australian women, following eight years of a national vaccination program.
    Garland SM; Cornall AM; Brotherton JML; Wark JD; Malloy MJ; Tabrizi SN;
    Vaccine; 2018 May; 36(23):3221-3230. PubMed ID: 29724506
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human papillomavirus prevalence and risk factors among Australian women 9-12 years after vaccine program introduction.
    Shilling H; Garland SM; Atchison S; Cornall AM; Brotherton JML; Bateson D; McNamee K; Kaldor JM; Hocking JS; Chen MY; Fairley CK; McNulty A; Bell C; Marshall L; Ooi C; Skinner SR; Murray G; Molano M; Tabrizi S; Machalek DA
    Vaccine; 2021 Aug; 39(34):4856-4863. PubMed ID: 34281743
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evidence for cross-protection but not type-replacement over the 11 years after human papillomavirus vaccine introduction.
    Covert C; Ding L; Brown D; Franco EL; Bernstein DI; Kahn JA
    Hum Vaccin Immunother; 2019; 15(7-8):1962-1969. PubMed ID: 30633598
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in the prevalence of human papillomavirus following a national bivalent human papillomavirus vaccination programme in Scotland: a 7-year cross-sectional study.
    Kavanagh K; Pollock KG; Cuschieri K; Palmer T; Cameron RL; Watt C; Bhatia R; Moore C; Cubie H; Cruickshank M; Robertson C
    Lancet Infect Dis; 2017 Dec; 17(12):1293-1302. PubMed ID: 28965955
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monitoring vaccine and non-vaccine HPV type prevalence in the post-vaccination era in women living in the Basilicata region, Italy.
    Carozzi F; Puliti D; Ocello C; Anastasio PS; Moliterni EA; Perinetti E; Serradell L; Burroni E; Confortini M; Mantellini P; Zappa M; Dominiak-Felden G
    BMC Infect Dis; 2018 Jan; 18(1):38. PubMed ID: 29334901
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Geographical disparities in human papillomavirus herd protection.
    Berenson AB; Hirth JM; Chang M
    Cancer Med; 2020 Jul; 9(14):5272-5280. PubMed ID: 32483924
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessing genital human papillomavirus genoprevalence in young Australian women following the introduction of a national vaccination program.
    Osborne SL; Tabrizi SN; Brotherton JM; Cornall AM; Wark JD; Wrede CD; Jayasinghe Y; Gertig DM; Pitts MK; Garland SM;
    Vaccine; 2015 Jan; 33(1):201-8. PubMed ID: 25444787
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is one dose of human papillomavirus vaccine as effective as three?: A national cohort analysis.
    Brotherton JM; Budd A; Rompotis C; Bartlett N; Malloy MJ; Andersen RL; Coulter KA; Couvee PW; Steel N; Ward GH; Saville M
    Papillomavirus Res; 2019 Dec; 8():100177. PubMed ID: 31319173
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human Papillomavirus Prevalence and Herd Immunity after Introduction of Vaccination Program, Scotland, 2009-2013.
    Cameron RL; Kavanagh K; Pan J; Love J; Cuschieri K; Robertson C; Ahmed S; Palmer T; Pollock KG
    Emerg Infect Dis; 2016 Jan; 22(1):56-64. PubMed ID: 26692336
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Very Low Prevalence of Vaccine Human Papillomavirus Types Among 18- to 35-Year Old Australian Women 9 Years Following Implementation of Vaccination.
    Machalek DA; Garland SM; Brotherton JML; Bateson D; McNamee K; Stewart M; Rachel Skinner S; Liu B; Cornall AM; Kaldor JM; Tabrizi SN
    J Infect Dis; 2018 Apr; 217(10):1590-1600. PubMed ID: 29425358
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decline in prevalence of human papillomavirus infection following vaccination among Australian Indigenous women, a population at higher risk of cervical cancer: The VIP-I study.
    McGregor S; Saulo D; Brotherton JML; Liu B; Phillips S; Skinner SR; Luey M; Oliver L; Stewart M; Tabrizi SN; Garland S; Kaldor JM
    Vaccine; 2018 Jul; 36(29):4311-4316. PubMed ID: 29880245
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HPV genotype prevalence in Australian women undergoing routine cervical screening by cytology status prior to implementation of an HPV vaccination program.
    Tabrizi SN; Brotherton JM; Stevens MP; Condon JR; McIntyre P; Smith D; Garland SM;
    J Clin Virol; 2014 Jul; 60(3):250-6. PubMed ID: 24854516
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Declines in HPV vaccine type prevalence in women screened for cervical cancer in the United States: Evidence of direct and herd effects of vaccination.
    Markowitz LE; Naleway AL; Lewis RM; Crane B; Querec TD; Weinmann S; Steinau M; Unger ER
    Vaccine; 2019 Jun; 37(29):3918-3924. PubMed ID: 31160099
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Asking about human papillomavirus vaccination and the usefulness of registry validation: a study of young women recruited using Facebook.
    Gunasekaran B; Jayasinghe Y; Brotherton JM; Fenner Y; Moore EE; Wark JD; Fletcher A; Tabrizi SN; Garland SM
    Vaccine; 2015 Feb; 33(6):826-31. PubMed ID: 25444782
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Substantial Decline in Vaccine-Type Human Papillomavirus (HPV) Among Vaccinated Young Women During the First 8 Years After HPV Vaccine Introduction in a Community.
    Kahn JA; Widdice LE; Ding L; Huang B; Brown DR; Franco EL; Bernstein DI
    Clin Infect Dis; 2016 Nov; 63(10):1281-1287. PubMed ID: 27655996
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.